<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Intern Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">Intern. Med</journal-id>
      <journal-id journal-id-type="doi">10.2169/internalmedicine.56.7363</journal-id>
      <journal-title-group>
        <journal-title>Internal Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0918-2918</issn>
      <issn pub-type="epub">1349-7235</issn>
      <publisher>
        <publisher-name>The Japanese Society of Internal Medicine</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">28090053</article-id>
      <article-id pub-id-type="pmc">5337468</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A Suspected Case of an Alveolar Haemorrhage Caused by Dasatinib</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Sakoda</surname>
            <given-names>Yoritake</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Arimori</surname>
            <given-names>Yojiro</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ueno</surname>
            <given-names>Masakatsu</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Matsumoto</surname>
            <given-names>Takafumi</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <aff id="aff1"><label>1</label>Department of Respiratory Medicine, St. Mary's Hospital, Japan</aff>
      </contrib-group>
      <author-notes>
        <fn>
          <p>Correspondence to Dr.&#x3000;Yoritake Sakoda, <email>y-sakota@st-mary-med.or.jp</email></p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>15</day>
        <month>1</month>
        <year>2017</year>
      </pub-date>
      <volume>56</volume>
      <issue>2</issue>
      <fpage>203</fpage>
      <lpage>206</lpage>
      <history>
        <date date-type="received">
          <day>4</day>
          <month>3</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>22</day>
          <month>5</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
          <license-p><!--CREATIVE COMMONS-->The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <p>A 39-year-old man treated with dasatinib for chronic myelogenous leukaemia presented to our hospital with haemoptysis, coughing, and dyspnoea. Chest radiography and computed tomography revealed ground-glass opacities and a crazy-paving pattern. Bronchoalveolar lavage was not performed due to serious hypoxemia and bleeding. Significant bleeding from the peripheral bronchi led to a diagnosis of an alveolar haemorrhage. Dasatinib-induced alveolar haemorrhaging was suspected based on the clinical findings. His condition improved immediately after dasatinib withdrawal and initiation of steroid therapy. Reports of alveolar haemorrhaging induced by dasatinib are rare. As such, this is considered an important case. </p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>alveolar haemorrhage</kwd>
        <kwd>dasatinib</kwd>
        <kwd>chronic myelogenous leukaemia</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Introduction</title>
      <p>Imatinib is a BCR-ABL tyrosine kinase inhibitor first introduced in 2001 that has markedly improved the prognosis of patients with chronic myelogenous leukaemia (CML). Nilotinib and dasatinib are second-generation tyrosine kinase inhibitors first introduced in 2009 that led to better outcomes than imatinib for the treatment of CML. However, these drugs also have various adverse effects. Here, we report a rare case of alveolar haemorrhaging induced by dasatinib.</p>
    </sec>
    <sec>
      <title>Case Report</title>
      <p>The patient was a 39-year-old man (height, 176 cm; weight, 107.9 kg; body mass index, 34.8) with a history of hypertension and CML. CML was diagnosed one year prior to the presentation and treated with dasatinib, with a good response. The patient was also on rabeprazole, amlodipine, and azilsartan. He had not been receiving other medications, including health foods or supplements. His coughing began two weeks before presentation. Haemoptysis appeared suddenly, followed by dyspnoea, and he was taken to the hospital in an ambulance. His vital signs were as follows: blood pressure 172/92 mmHg, pulse 115 beats/min, temperature 38.3&#x2103;, percutaneous oxygen saturation 85% (reservoir mask 10 L/min), and respiration 31 breaths/min. Coarse crackling was audible in both lungs. The peripheral leukocyte count was 6,360 /&#x3BC;L, and the serum C-reactive protein level was 0.9 mg/dL (<xref ref-type="table" rid="t001">Table</xref>). Blood tests did not reveal any coagulation abnormality. His levels of brain natriuretic peptide (BNP) were mildly elevated (32.8 ng/mL), and the levels of sialylated carbohydrate antigen (KL-6) and surfactant protein-D (SP-D) were also elevated (836 U/mL and 259.6 ng/mL, respectively). The tests for autoantibodies were negative, including the findings for anti-neutrophil cytoplasmic antibody (ANCA). A sputum culture was negative for bacteria, including acid-fast bacilli. Chest X-ray revealed ground-glass opacity and consolidation in both lungs (<xref ref-type="fig" rid="g001">Fig. 1</xref>). Chest computed tomography revealed diffuse ground-glass opacity and consolidation in both lungs around the bronchial vascular bundles, along with a crazy-paving pattern (<xref ref-type="fig" rid="g002">Fig. 2</xref>). The differential diagnosis included respiratory infection, interstitial pneumonia, alveolar haemorrhaging, and heart failure. There was no oedema in the lower extremities, and his cardiac function was within the normal range based on the findings of echocardiography. Thus, the mild brain-type natriuretic peptide (BNP) elevation was considered to be due to his high blood pressure, and heart failure was ruled out. Bronchoalveolar lavage (BAL) was not possible due to severe hypoxemia. His symptoms and imaging findings suggested the possibility of alveolar haemorrhaging, and treatment was initiated accordingly.</p>
      <table-wrap id="t001" orientation="portrait" position="float">
        <label>Table.</label>
        <caption>
          <p>Laboratory Data on Admission.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Hematology</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">Immunology</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Red blood cell count</td>
              <td align="right" rowspan="1" colspan="1">418&#xD7;10<sup>4</sup></td>
              <td rowspan="1" colspan="1">/&#x3BC;L</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Anti-nulcear antibody</td>
              <td align="right" rowspan="1" colspan="1">(-)</td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Hemoglobin</td>
              <td align="right" rowspan="1" colspan="1">12</td>
              <td rowspan="1" colspan="1">g/dL</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Rheumatoid factor</td>
              <td align="right" rowspan="1" colspan="1">&lt;5</td>
              <td rowspan="1" colspan="1">IU/mL</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Hematocrit</td>
              <td align="right" rowspan="1" colspan="1">35.9</td>
              <td rowspan="1" colspan="1">%</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> MPO-ANCA</td>
              <td align="right" rowspan="1" colspan="1">&lt;1.0</td>
              <td rowspan="1" colspan="1">U/mL</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> White blood cell coun</td>
              <td align="right" rowspan="1" colspan="1">6,360</td>
              <td rowspan="1" colspan="1">/&#x3BC;L</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> PR3-ANCA</td>
              <td align="right" rowspan="1" colspan="1">&lt;1.0</td>
              <td rowspan="1" colspan="1">U/mL</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Neutrophil</td>
              <td align="right" rowspan="1" colspan="1">63</td>
              <td rowspan="1" colspan="1">%</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Anti-GBM antibody</td>
              <td align="right" rowspan="1" colspan="1">&lt;2.0</td>
              <td rowspan="1" colspan="1">U/mL</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Eosinophil</td>
              <td align="right" rowspan="1" colspan="1">1</td>
              <td rowspan="1" colspan="1">%</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Basocyte</td>
              <td align="right" rowspan="1" colspan="1">0</td>
              <td rowspan="1" colspan="1">%</td>
              <td rowspan="1" colspan="1">Biochemistry</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Lymphocyte</td>
              <td align="right" rowspan="1" colspan="1">33</td>
              <td rowspan="1" colspan="1">%</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Total Protein</td>
              <td align="right" rowspan="1" colspan="1">7.3</td>
              <td rowspan="1" colspan="1">g/dL</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Monocyte</td>
              <td align="right" rowspan="1" colspan="1">3</td>
              <td rowspan="1" colspan="1">%</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Albumin</td>
              <td align="right" rowspan="1" colspan="1">4.5</td>
              <td rowspan="1" colspan="1">g/dL</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Platelet count</td>
              <td align="right" rowspan="1" colspan="1">16.9&#xD7;10<sup>4</sup></td>
              <td rowspan="1" colspan="1">/&#x3BC;L</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Total bilirubin</td>
              <td align="right" rowspan="1" colspan="1">0.49</td>
              <td rowspan="1" colspan="1">mg/dL</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> AST</td>
              <td align="right" rowspan="1" colspan="1">20</td>
              <td rowspan="1" colspan="1">IU/L</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Coagulation</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> ALT</td>
              <td align="right" rowspan="1" colspan="1">20</td>
              <td rowspan="1" colspan="1">IU/L</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> PT</td>
              <td align="right" rowspan="1" colspan="1">11.5</td>
              <td rowspan="1" colspan="1">s</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> LDH</td>
              <td align="right" rowspan="1" colspan="1">247</td>
              <td rowspan="1" colspan="1">IU/L</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> PT-INR</td>
              <td align="right" rowspan="1" colspan="1">0.98</td>
              <td rowspan="1" colspan="1"/>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> ALP</td>
              <td align="right" rowspan="1" colspan="1">127</td>
              <td rowspan="1" colspan="1">IU/L</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> APTT</td>
              <td align="right" rowspan="1" colspan="1">30.5</td>
              <td rowspan="1" colspan="1">s</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> &#x3B3;GTP</td>
              <td align="right" rowspan="1" colspan="1">43</td>
              <td rowspan="1" colspan="1">IU/L</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Fibrinogen</td>
              <td align="right" rowspan="1" colspan="1">350</td>
              <td rowspan="1" colspan="1">mg/dL</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Urea nitrogen</td>
              <td align="right" rowspan="1" colspan="1">14.4</td>
              <td rowspan="1" colspan="1">mg/dL</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> FDP</td>
              <td align="right" rowspan="1" colspan="1">&lt;2.5</td>
              <td rowspan="1" colspan="1">&#x3BC;g/mL</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Creatinine</td>
              <td align="right" rowspan="1" colspan="1">0.79</td>
              <td rowspan="1" colspan="1">mg/dL</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Glucose</td>
              <td align="right" rowspan="1" colspan="1">113</td>
              <td rowspan="1" colspan="1">mg/dL</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Serology</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Sodium</td>
              <td align="right" rowspan="1" colspan="1">144</td>
              <td rowspan="1" colspan="1">mEq/L</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> CRP</td>
              <td align="right" rowspan="1" colspan="1">0.9</td>
              <td rowspan="1" colspan="1">mg/dL</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Potassium</td>
              <td align="right" rowspan="1" colspan="1">3.88</td>
              <td rowspan="1" colspan="1">mEq/L</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> KL-6</td>
              <td align="right" rowspan="1" colspan="1">836</td>
              <td rowspan="1" colspan="1">U/mL</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Chloride</td>
              <td align="right" rowspan="1" colspan="1">105.7</td>
              <td rowspan="1" colspan="1">mEq/L</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> SP-D</td>
              <td align="right" rowspan="1" colspan="1">259.6</td>
              <td rowspan="1" colspan="1">ng/mL</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> CMV-C7HRP</td>
              <td align="right" rowspan="1" colspan="1">(-)</td>
              <td rowspan="1" colspan="1"/>
              <td colspan="3" rowspan="1">Blood gas analysis(O<sub>2</sub> 10l/min reservoir mask)</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> &#x3B2;-D glucan</td>
              <td align="right" rowspan="1" colspan="1">&lt;2.8</td>
              <td rowspan="1" colspan="1">pg/mL</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> ph</td>
              <td align="right" rowspan="1" colspan="1">7.382</td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Procalcitonin</td>
              <td align="right" rowspan="1" colspan="1">&lt;0.02</td>
              <td rowspan="1" colspan="1">ng/mL</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> PaO<sub>2</sub></td>
              <td align="right" rowspan="1" colspan="1">61</td>
              <td rowspan="1" colspan="1">Torr</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> PaCO<sub>2</sub></td>
              <td align="right" rowspan="1" colspan="1">44.3</td>
              <td rowspan="1" colspan="1">Torr</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> HCO<sub>3</sub><sup>-</sup></td>
              <td align="right" rowspan="1" colspan="1">25.7</td>
              <td rowspan="1" colspan="1">mEq/L</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> BE</td>
              <td align="right" rowspan="1" colspan="1">0.9</td>
              <td rowspan="1" colspan="1">mEq/L</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> SaO<sub>2</sub></td>
              <td align="right" rowspan="1" colspan="1">85</td>
              <td rowspan="1" colspan="1">%</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>PT:prothrombin time, PT-INR:prothrombin time international normalized ratio, APTT:activated partial thromboplastin time, FDP:fibrinogen degradation products, CRP:C-reactive protein, KL-6:sialylated carbohydrate antigen, SP-D:surfactant protein-D, CMV:cytomegalovirus, MPO- ANCA:myeloperoxidase anti-neutrophil cytoplasmic antibody, PR3-ANCA:proteinase3 anti- neutrophil cytoplasmic antibody, GBM:glomerular basement membrane, AST:aspartate aminotransferase, ALT:alanine aminotransferase, LDH:lactate dehydrogenase, ALP:alkaline phosphatase, &#x3B3;GTP:gamma glutamyl transpeptitase, BE:base excess</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <fig id="g001" orientation="portrait" position="float">
        <label>Figure 1.</label>
        <caption>
          <p>Chest roentgenogram on admission shows bilateral ground-glass opacity and consolidation.</p>
        </caption>
        <graphic xlink:href="1349-7235-56-0203-g001"/>
      </fig>
      <fig id="g002" orientation="portrait" position="float">
        <label>Figure 2.</label>
        <caption>
          <p>Chest CT on admission shows ground-glass opacity and consolidation in both lungs around bronchial vascular bundles, along with crazy-paving pattern.</p>
        </caption>
        <graphic xlink:href="1349-7235-56-0203-g002"/>
      </fig>
      <p>Given the possibility of drug-induced alveolar haemorrhaging, all oral medications (rabeprazole, amlodipine, azilsartan, and dasatinib) were withdrawn after hospitalisation. We started steroid pulse therapy with methylprednisolone at 1 g/day for 3 days just after hospitalisation. Although there was little increase in the inflammation and no elevation of procalcitonin, we initiated meropenem, micafungin, and ganciclovir given the possibility of infection complicated by his immunocompromised state owing to haematological malignancy and chemotherapy. Respiratory failure progressed on the second day after hospitalisation, so tracheal intubation was performed and respiratory management initiated. We performed a bronchoscopic examination just after intubation, which revealed significant intratracheal haemoptysis and bleeding in the peripheral bronchi. BAL was not possible due to the patient's severe hypoxemia and active bleeding, but alveolar haemorrhaging was strongly suspected based on intratracheal bleeding. His respiratory status and imaging findings improved immediately with steroid pulse therapy (<xref ref-type="fig" rid="g003">Fig. 3</xref>). Maintenance therapy was initiated with methylprednisolone at 80 mg/day after the completion of steroid pulse therapy. Artificial respiration was terminated on Day 8 after hospitalization, and oxygen therapy was ended on Day 9. The steroid administration was tapered, and no signs of recurrence were observed. The patient was considered fit to be discharged on Day 33.</p>
      <fig id="g003" orientation="portrait" position="float">
        <label>Figure 3.</label>
        <caption>
          <p>Chest roentgenogram 4 days after administration of PSL therapy revealed remarkable improvement.</p>
        </caption>
        <graphic xlink:href="1349-7235-56-0203-g003"/>
      </fig>
    </sec>
    <sec>
      <title>Discussion</title>
      <p>Dasatinib is a molecular-targeting drug that inhibits BCR-ABL tyrosine kinase, which is involved in the aetiology of CML and Philadelphia-chromosome-positive acute lymphoid leukaemia. The activity of dasatinib is 325 times that of imatinib, and it has become an important drug for CML treatment (<xref rid="B1" ref-type="bibr">1</xref>). However, there are reports of adverse effects such as bone marrow suppression, bleeding (cerebral haemorrhaging, lower endocranial bleeding and gastrointestinal bleeding), and body fluid retention (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>). In the respiratory system, pleural effusion and interstitial pneumonia are serious adverse effects (<xref rid="B4" ref-type="bibr">4</xref>).</p>
      <p>Only a few cases of alveolar haemorrhaging have been reported in post-marketing surveillance. Our literature search retrieved only one case report that was presented at a meeting in Japan (<xref rid="B5" ref-type="bibr">5</xref>). BAL fluid is considered important for the definitive diagnosis of alveolar haemorrhaging (<xref rid="B6" ref-type="bibr">6</xref>). Unfortunately, we were unable to perform BAL due to serious hypoxemia, but we did observe significant intratracheal haemoptysis just after tracheal intubation. The presence of bleeding from the trachea suggested bleeding in the peripheral respiratory tract and alveoli, and computed tomography also revealed subpleural sparing opacities and a crazy-paving pattern, with superimposition of ground-glass opacities and the reticular pattern, which did not rule out the possibility of alveolar haemorrhage (<xref rid="B7" ref-type="bibr">7</xref>-<xref rid="B9" ref-type="bibr">9</xref>). These observations led to a clinical diagnosis of alveolar haemorrhaging.</p>
      <p>Diseases resulting in alveolar haemorrhaging include ANCA-related vasculitis, collagen diseases (e.g. systemic lupus erythematosus), Goodpasture syndrome, heart failure, and adverse drug effects (<xref rid="B10" ref-type="bibr">10</xref>). Antinuclear antibodies, myeloperoxidase-ANCA, proteinase 3-ANCA, and antiglomerular basement membrane antibodies were all negative in our case. We also did not detect any signs of heart failure on a physical examination or in the laboratory findings, including echocardiography. This led us to consider the possibility of drug-induced alveolar haemorrhaging. Our patient was taking rabeprazole, amlodipine, and azilsartan, as well as dasatinib. It was not clear which drug caused the alveolar haemorrhaging, so all of the drugs were discontinued after hospitalisation. After discontinuation of artificial respiration, all of the drugs except dasatinib were reinitiated, and there was no recurrence of alveolar haemorrhaging. Thus, we concluded that dasatinib was the cause of the alveolar haemorrhage.</p>
      <p>Drugs often reported to induce pulmonary haemorrhaging include anticoagulants (<xref rid="B11" ref-type="bibr">11</xref>), propylthiouracil (<xref rid="B12" ref-type="bibr">12</xref>), amiodarone (<xref rid="B13" ref-type="bibr">13</xref>), and methotrexate (<xref rid="B14" ref-type="bibr">14</xref>). The mechanism underlying haemorrhage can be divided into three categories: 1) excessive anticoagulant therapy, 2) type 3 or 4 allergy, and 3) cytotoxicity (<xref rid="B15" ref-type="bibr">15</xref>). The suggested cause of pulmonary complications induced by dasatinib, such as pleural effusion and interstitial pneumonia, is the inhibition of platelet-derived growth factor (<xref rid="B16" ref-type="bibr">16</xref>) and participation of large granular lymphocytes (<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref>); however, the exact mechanism is unknown. KL-6 and SP-D levels were elevated in our case, possibly suggesting at least the involvement of alveolar epithelial and interstitial damage. In our case, alveolar haemorrhaging developed approximately one year after initiating dasatinib. The onset of drug-induced lung injury varies from a few days to several years with drug treatment and can last for several months after drug cessation (<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B14" ref-type="bibr">14</xref>). It is therefore difficult to estimate the exact time of onset (<xref rid="B19" ref-type="bibr">19</xref>). Since each drug has a characteristic onset pattern, the accumulation of cases is important.</p>
      <p>Our case will require continuous medical treatment for CML and the patient is now receiving nilotinib. Nilotinib is a BCR-ABL tyrosine kinase inhibitor like dasatinib but is reported to have few cross-intolerances (<xref rid="B20" ref-type="bibr">20</xref>) and is considered safe (<xref rid="B21" ref-type="bibr">21</xref>). However, there are reports of cross-intolerance among BCR-ABL tyrosine kinase inhibitors such as dasatinib. Dasatinib use will continue to increase in the future for the treatment of CML. Alveolar haemorrhaging is a potentially fatal adverse effect, similar to pleural effusion and interstitial pneumonia, and thus should be a consideration when using the drug.</p>
    </sec>
    <sec>
      <title>The authors state that they have no Conflict of Interest (COI).</title>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <label>1.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O'Hare</surname><given-names>T</given-names></name>, <name><surname>Walters</surname><given-names>DK</given-names></name>, <name><surname>Stoffregen</surname><given-names>EP</given-names></name>, <etal>et al</etal></person-group>
<article-title>In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants</article-title>. <source>Cancer Res</source>
<volume>65</volume>: <fpage>4500</fpage>-<lpage>4505</lpage>, <year>2005</year>.<pub-id pub-id-type="pmid">15930265</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kantarjian</surname><given-names>H</given-names></name>, <name><surname>Shah</surname><given-names>NP</given-names></name>, <name><surname>Hochhaus</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia</article-title>. <source>N Engl J Med</source>
<volume>362</volume>: <fpage>2260</fpage>-<lpage>2270</lpage>, <year>2010</year>.<pub-id pub-id-type="pmid">20525995</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jabbour</surname><given-names>E</given-names></name>, <name><surname>Kantarjian</surname><given-names>HM</given-names></name>, <name><surname>Saglio</surname><given-names>G</given-names></name>, <etal>et al</etal></person-group>
<article-title>Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial(DASISION)</article-title>. <source>Blood</source>
<volume>123</volume>: <fpage>494</fpage>-<lpage>500</lpage>, <year>2014</year>.<pub-id pub-id-type="pmid">24311723</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4.</label>
        <mixed-citation publication-type="book"><source>SPRYCEL<sup>&#x24C7;</sup> Drug interview form version9 Britol-Myers Squibb</source>.</mixed-citation>
      </ref>
      <ref id="B5">
        <label>5.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nishikawa</surname><given-names>A</given-names></name>, <name><surname>Fujiwara</surname><given-names>S</given-names></name>, <name><surname>Hatano</surname><given-names>K</given-names></name>, <etal>et al</etal></person-group>
<article-title>A case of pulmonary and urinary bleedings caused by dasatinib in posttransplant reccurent ph-ALL</article-title>. <source>Jpn J Clin Hematol</source>
<volume>50</volume>: <fpage>1168</fpage>, <year>2009</year> (in Japanese).</mixed-citation>
      </ref>
      <ref id="B6">
        <label>6.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lassence</surname><given-names>AD</given-names></name>, <name><surname>Fleury-Feith</surname><given-names>J</given-names></name>, <name><surname>Escudier</surname><given-names>E</given-names></name>, <name><surname>Beaune</surname><given-names>J</given-names></name>, <name><surname>Bernaudin</surname><given-names>JF</given-names></name>, <name><surname>Cordonnier</surname><given-names>C</given-names></name></person-group>
<article-title>Alveolar hemorrhage. Diagnostic criteria and results in 194 immunocompromised hosts</article-title>. <source>Am J Respir Crit Care Med</source>
<volume>151</volume>: <fpage>157</fpage>-<lpage>163</lpage>, <year>1995</year>.<pub-id pub-id-type="pmid">7812547</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seo</surname><given-names>JB</given-names></name>, <name><surname>Im</surname><given-names>JG</given-names></name>, <name><surname>Chung</surname><given-names>JW</given-names></name>, <etal>et al</etal></person-group>
<article-title>Pulmonary vasculitis: the spectrum of radiological findings</article-title>. <source>Br J Radiol</source>
<volume>73</volume>: <fpage>1224</fpage>-<lpage>1231</lpage>, <year>2000</year>.<pub-id pub-id-type="pmid">11144805</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Primack</surname><given-names>SL</given-names></name>, <name><surname>Miller</surname><given-names>RR</given-names></name>, <name><surname>Muller</surname><given-names>NL</given-names></name></person-group>
<article-title>Diffuse pulmonary hemorrhage: clinical, pathologic, and imaging features</article-title>. <source>Am J Roentgenol</source>
<volume>164</volume>: <fpage>295</fpage>-<lpage>300</lpage>, <year>1995</year>.<pub-id pub-id-type="pmid">7839958</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seely</surname><given-names>JM</given-names></name>, <name><surname>Effmann</surname><given-names>EL</given-names></name>, <name><surname>Muller</surname><given-names>NL</given-names></name></person-group>
<article-title>High-resolution CT of pediatric lung disease: imaging findings</article-title>. <source>Am J Roentgenol</source>
<volume>168</volume>: <fpage>1269</fpage>-<lpage>1275</lpage>, <year>1997</year>.<pub-id pub-id-type="pmid">9129425</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Green</surname><given-names>RJ</given-names></name>, <name><surname>Ruoss</surname><given-names>SJ</given-names></name>, <name><surname>Kraft</surname><given-names>SA</given-names></name>, <etal>et al</etal></person-group>
<article-title>Pulmonary capillaritis and alveolar hemorrhage-update on diagnosis and management</article-title>. <source>Chest</source>
<volume>10</volume>: <fpage>1305</fpage>-<lpage>1316</lpage>, <year>1996</year>.</mixed-citation>
      </ref>
      <ref id="B11">
        <label>11.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Erdogan</surname><given-names>D</given-names></name>, <name><surname>Kocaman</surname><given-names>O</given-names></name>, <name><surname>Oflaz</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group>
<article-title>Alveolar hemorrhage associated with warfarin therapy: a case report and literature review</article-title>. <source>Int J Cardiovasc Imaging</source>
<volume>20</volume>: <fpage>155</fpage>-<lpage>159</lpage>, <year>2004</year>.<pub-id pub-id-type="pmid">15068147</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dhillon</surname><given-names>SS</given-names></name>, <name><surname>Singh</surname><given-names>D</given-names></name>, <name><surname>Doe</surname><given-names>N</given-names></name>, <etal>et al</etal></person-group>
<article-title>Diffuse alveolar hemorrhage and pulmonary capillaritis due to propylthiouracil</article-title>. <source>Chest</source>
<volume>116</volume>: <fpage>1485</fpage>-<lpage>1488</lpage>, <year>1999</year>.<pub-id pub-id-type="pmid">10559122</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iskandar</surname><given-names>SB</given-names></name>, <name><surname>Abi-Saleh</surname><given-names>B</given-names></name>, <name><surname>Keith</surname><given-names>RL</given-names></name>, <etal>et al</etal></person-group>
<article-title>Amiodarone-induced alveolar hemorrhage</article-title>. <source>South Med J</source>
<volume>99</volume>: <fpage>383</fpage>-<lpage>387</lpage>, <year>2006</year>.<pub-id pub-id-type="pmid">16634249</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zisman</surname><given-names>DA</given-names></name>, <name><surname>McCune</surname><given-names>WJ</given-names></name>, <name><surname>Tino</surname><given-names>G</given-names></name>, <etal>et al</etal></person-group>
<article-title>Drug-induced pneumonitis: the role of methotrexate</article-title>. <source>Sarcoidosis Vasc Diffuse Lung Dis</source>
<volume>18</volume>: <fpage>243</fpage>-<lpage>252</lpage>, <year>2001</year>.<pub-id pub-id-type="pmid">11587095</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>MI</given-names></name>, <name><surname>Fontenot</surname><given-names>AP</given-names></name></person-group>
<article-title>Drug-induced diffuse alveolar hemorrhage syndromes and vasculitis</article-title>. <source>Clin Chest Med</source>
<volume>25</volume>: <fpage>133</fpage>-<lpage>140</lpage>, <year>2004</year>.<pub-id pub-id-type="pmid">15062605</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kelly</surname><given-names>K</given-names></name>, <name><surname>Swords</surname><given-names>R</given-names></name>, <name><surname>Mahalingam</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>Serosal inflammation (pleural and pericardial effusions) related to tyrosin kinase inhibitors</article-title>. <source>Target Oncol</source>
<volume>4</volume>: <fpage>99</fpage>-<lpage>105</lpage>, <year>2009</year>.<pub-id pub-id-type="pmid">19381453</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mustjoki</surname><given-names>S</given-names></name>, <name><surname>Ekblom</surname><given-names>M</given-names></name>, <name><surname>Arstila</surname><given-names>TP</given-names></name>, <etal>et al</etal></person-group>
<article-title>Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy</article-title>. <source>Leukemia</source>
<volume>23</volume>: <fpage>1398</fpage>-<lpage>1405</lpage>, <year>2009</year>.<pub-id pub-id-type="pmid">19295545</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qiu</surname><given-names>ZY</given-names></name>, <name><surname>Xu</surname><given-names>W</given-names></name>, <name><surname>Li</surname><given-names>Jy</given-names></name></person-group>
<article-title>Large granular lymphocytosis during dasatinib therapy</article-title>. <source>Cancer Biol Ther</source>
<volume>15</volume>: <fpage>247</fpage>-<lpage>255</lpage>, <year>2014</year>.<pub-id pub-id-type="pmid">24352048</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19.</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>M</given-names></name>, <name><surname>King</surname><given-names>TE</given-names><suffix>Jr</suffix></name></person-group>
<source>Interstitial Lung Disease 5th ed</source>. <publisher-name>People's Medical Publishing House</publisher-name>, <publisher-loc>USA</publisher-loc>, <year>2011</year>: <fpage>637</fpage>-<lpage>688</lpage>.</mixed-citation>
      </ref>
      <ref id="B20">
        <label>20.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baccarani</surname><given-names>M</given-names></name>, <name><surname>Deininger</surname><given-names>MW</given-names></name>, <name><surname>Rosti</surname><given-names>G</given-names></name>, <etal>et al</etal></person-group>
<article-title>European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013</article-title>. <source>Blood</source>
<volume>122</volume>: <fpage>872</fpage>-<lpage>884</lpage>, <year>2013</year>.<pub-id pub-id-type="pmid">23803709</pub-id></mixed-citation>
      </ref>
      <ref id="B21">
        <label>21.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nagata</surname><given-names>Y</given-names></name>, <name><surname>Fukuda</surname><given-names>S</given-names></name>, <name><surname>Kobayashi</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group>
<article-title>Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase</article-title>. <source>Int J Hematol</source>
<volume>91</volume>: <fpage>539</fpage>-<lpage>541</lpage>, <year>2010</year>.<pub-id pub-id-type="pmid">20191333</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <label>22.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Furuta</surname><given-names>R</given-names></name>, <name><surname>Kawaguchi</surname><given-names>T</given-names></name>, <name><surname>Miyagawa</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group>
<article-title>A CML pt experiencing imatinib-induced interstitial pneumonia(IP) had recurrent IP with nilotinib</article-title>. <source>Jpn J Clin Hematol</source>
<volume>54</volume>: <fpage>1386</fpage>, <year>2013</year> (in Japanese, Abstract in English).</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
